Syndax Pharmaceuticals Inc [SNDX] stock is trading at $19.25, up 1.91%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SNDX shares have gain 7.36% over the last week, with a monthly amount drifted -4.75%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on June 28, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $37. Previously, Scotiabank downgraded its rating to Sector Perform on January 31, 2024, and dropped its price target to $23. On December 22, 2023, Mizuho initiated with a Buy rating and assigned a price target of $45 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $29 on October 25, 2023. Goldman initiated its recommendation with a Buy and recommended $30 as its price target on October 11, 2023. In a note dated July 11, 2023, Guggenheim initiated an Buy rating and provided a target price of $40 on this stock.
Syndax Pharmaceuticals Inc [SNDX] stock has fluctuated between $11.22 and $25.34 over the past year. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $19.25 at the most recent close of the market. An investor can expect a potential return of 87.01% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -71.36%, Pretax Profit Margin comes in at -65.43%, and Net Profit Margin reading is -65.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.57 and Total Capital is -0.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.77 points at the first support level, and at 18.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.66, and for the 2nd resistance point, it is at 20.07.
Ratios To Look Out For
For context, Syndax Pharmaceuticals Inc’s Current Ratio is 10.50. As well, the Quick Ratio is 10.50, while the Cash Ratio is 2.48. Considering the valuation of this stock, the price to sales ratio is 468.05, the price to book ratio is 3.77.
Transactions by insiders
Recent insider trading involved Goldan Keith A., Chief Financial Officer, that happened on Jun 14 ’24 when 1250.0 shares were purchased.
